My coauthors and I thank Drs. Scrivani, Mehta, Mathews, and Maciewicz for their letter about our manuscript “Diagnostic significance of carbamazepine and trigger zones in trigeminal neuralgia.” They pointed out that our manuscript contains basic errors in methodology, data collection, and interpretation of results. Although our study is a clinical-based, retrospective study, and not of high quality, we believed that it contains some important and interesting issues:1)We raise again the importance of the problem concerning lack of globally-accepted criteria for trigeminal neuralgia (TN).2)We were able to demonstrate the possibility that the carbamazepine is effective and that the presence of a trigger zone might be a useful indicator for TN in our limited subjects.3)It is generally accepted that TN is not difficult to diagnose because its symptoms are specific. However, we reconfirmed that there are other orofacial pain syndromes that are similar to TN, including atypical facial pain. Although these results are not new, we have presented raw clinical data. We agree with their comment that definite research of TN diagnostic criteria is fundamentally important. We suspect that our rudimentary study is a contribution to this.